These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23964940)

  • 21. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Eriksson C; Marsal J; Bergemalm D; Vigren L; Björk J; Eberhardson M; Karling P; Söderman C; ; Myrelid P; Cao Y; Sjöberg D; Thörn M; Karlén P; Hertervig E; Strid H; Ludvigsson JF; Almer S; Halfvarson J
    Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M; Cross RK
    Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.
    Hoffmann P; Krisam J; Stremmel W; Gauss A
    Dig Dis; 2019; 37(1):33-44. PubMed ID: 30134234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biological treatment of inflammatory bowel diseases in children in the years 2004-2013 in Poland].
    Iwańczak B; Ryzko J; Kierkuś J; Jankowski P; Sładek M; Wasilewska A; Landowski P; Szczepanik M; Krzesiek E; Sienkiewicz E; Szaflarska-Popławska A; Wiecek S; Kwiecien J; Kacperska M; Korczowski B; Maślana J
    Pol Merkur Lekarski; 2014 May; 36(215):311-5. PubMed ID: 24964507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.
    Khanna R; Chande N; Vermeire S; Sandborn WJ; Parker CE; Feagan BG
    Inflamm Bowel Dis; 2016 Jul; 22(7):1737-43. PubMed ID: 27306074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease.
    Arseneau KO; Cominelli F
    Clin Pharmacol Ther; 2015 Jan; 97(1):22-8. PubMed ID: 25670380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
    Hindryckx P; Vande Casteele N; Novak G; Khanna R; D'Haens G; Sandborn WJ; Danese S; Jairath V; Feagan BG
    J Crohns Colitis; 2018 Jan; 12(1):105-119. PubMed ID: 28961959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
    Domènech E; Gisbert JP
    Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Not Available].
    Bliampti AL; Seidelin JB; Burisch J
    Ugeskr Laeger; 2024 Apr; 186(18):. PubMed ID: 38704716
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
    Wyant T; Fedyk E; Abhyankar B
    J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?
    Khanna R; Mosli MH; Feagan BG
    Dig Dis; 2016; 34(1-2):153-9. PubMed ID: 26982012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
    Yajnik V; Khan N; Dubinsky M; Axler J; James A; Abhyankar B; Lasch K
    Adv Ther; 2017 Feb; 34(2):542-559. PubMed ID: 28070861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Digestive Disease Week 2006. Therapies for Crohn's disease and ulcerative colitis. 21-15 May 2006, Los Angeles, CA, USA.
    Aylett P
    IDrugs; 2006 Jul; 9(7):452-4. PubMed ID: 16821150
    [No Abstract]   [Full Text] [Related]  

  • 38. [Not Available].
    Novacek G; Dejaco C; Gröchenig HP; Högenauer C; Knoflach P; Miehsler W; Moschen A; Petritsch W; Vogelsang H; Tilg H
    Z Gastroenterol; 2016 May; 54(5):456-67. PubMed ID: 26982099
    [No Abstract]   [Full Text] [Related]  

  • 39. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
    Gearry RB; Irving PM
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
    [No Abstract]   [Full Text] [Related]  

  • 40. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
    Battat R; Ma C; Jairath V; Khanna R; Feagan BG
    Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.